The US FDA has approved Mitapivat (Aqvesme), the first oral therapy for anemia in adults with alpha or beta thalassemia, offering a new treatment beyond blood transfusions. This drug activates energy production in red blood cells, improving hemoglobin levels and reducing fatigue. While trials showed significant benefits, it awaits Indian regulatory approval.FDA approves first oral drug for thalassemia anemia, offering new hope beyond blood transfusions
The US FDA has approved Mitapivat (Aqvesme), the first oral therapy for anemia in adults with alpha or beta thalassemia, offering a new treatment beyond blood transfusions. This drug activates energy production in red blood cells, improving hemoglobin levels and reducing fatigue. While trials showed significant benefits, it awaits Indian regulatory approval.
